ArticleJournal of translational medicine2020
Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas.
Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Exploring the role of Disulfidptosis in glioma progression: insights into tumor heterogeneity and therapeutic potential through single-cell RNA sequencing.Discover oncology · 2024Article
- Comprehensive analysis of CYBB as a prognostic marker and therapeutic target in glioma: A bioinformatics approach.Heliyon · 2024Article
- Review
- Effects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells.Pharmaceutics · 2023Article
- Development of a prognostic Neutrophil Extracellular Traps related lncRNA signature for soft tissue sarcoma using machine learning.Frontiers in immunology · 2023Article
- Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.Translational cancer research · 2022Article
- A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma.Journal of oncology · 2022Article
- B2M overexpression correlates with malignancy and immune signatures in human gliomas.Scientific reports · 2021Article
- TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas.Frontiers in immunology · 2021Article
- The molecular feature of macrophages in tumor immune microenvironment of glioma patients.Computational and structural biotechnology journal · 2021Article
- The Predictive Value of Monocytes in Immune Microenvironment and Prognosis of Glioma Patients Based on Machine Learning.Frontiers in immunology · 2021Article
- Ferroptosis-Related Gene Signature Promotes Ovarian Cancer by Influencing Immune Infiltration and Invasion.Journal of oncology · 2021Article
- A Prognostic Model for Brain Glioma Patients Based on 9 Signature Glycolytic Genes.BioMed research international · 2021Article
- m5C-Related Signatures for Predicting Prognosis in Cutaneous Melanoma with Machine Learning.Journal of oncology · 2021Article
- HOXA5 Is Recognized as a Prognostic-Related Biomarker and Promotes Glioma Progression Through Affecting Cell Cycle.Frontiers in oncology · 2021Article
- Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.Frontiers in immunology · 2021Article
- Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer.Frontiers in immunology · 2021Article
- Correction to: Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas.Journal of translational medicine · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapies targeting glioblastoma (GBM) have led to significant improvements in patient outcomes. TOX is closely associated with the immune environment surrounding tumors, but its role in gliomas is not fully understood.
methodsUsing data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), we analyzed the transcriptomes of 1691 WHO grade I-IV human glioma samples. The R language was used to perform most of the statistical analyses. Somatic mutations and somatic copy number variation (CNV) were analyzed using GISTIC 2.0.
resultsTOX was down-regulated in malignant gliomas compared to low grade gliomas, and upregulated in the proneural and IDH mutant subtypes of GBM. TOX
conclusionTOX has the potential to be a new prognostic marker for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.